Literature DB >> 22918492

Biosimilars in rheumatology: a view from Latin America.

Eduardo Mysler, Morton Scheinberg.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22918492     DOI： 10.1007/s10067-012-2068-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  7 in total

Review 1.  The advent of biosimilar therapies in rheumatology--"O brave new world".

Authors:  Morton A Scheinberg; Jonathan Kay
Journal:  Nat Rev Rheumatol       Date:  2012-06-05       Impact factor: 20.543

Review 2.  The challenge of biosimilars.

Authors:  H Mellstedt; D Niederwieser; H Ludwig
Journal:  Ann Oncol       Date:  2007-09-14       Impact factor: 32.976

3.  Developing the nation's biosimilars program.

Authors:  Steven Kozlowski; Janet Woodcock; Karen Midthun; Rachel Behrman Sherman
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

Review 4.  Biosimilars--global issues, national solutions.

Authors:  Ivana Knezevic; Elwyn Griffiths
Journal:  Biologicals       Date:  2011-09-15       Impact factor: 1.856

5.  Biosimilars: the debate continues.

Authors:  Robert A Colbert; Bruce N Cronstein
Journal:  Arthritis Rheum       Date:  2011-10

Review 6.  Advances in the treatment of inflammatory arthritis.

Authors:  David S Pisetsky; Michael M Ward
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-04       Impact factor: 4.098

7.  Biosimilars: a regulatory perspective from America.

Authors:  Jonathan Kay
Journal:  Arthritis Res Ther       Date:  2011-05-12       Impact factor: 5.156
  7 in total
  8 in total

Review 1.  Biosimilars: clinical interpretation and implications for drug development.

Authors:  Eduardo Mysler
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

2.  PANLAR consensus statement on biosimilars.

Authors:  S C Kowalski; J A Benavides; P A B Roa; C Galarza-Maldonado; C V Caballero-Uribe; E R Soriano; C Pineda; V F Azevedo; G Avila-Pedretti; A M Babini; A Cachafeiro-Vilar; M Cifuentes-Alvarado; S B Cohen; P E Díaz; L Diaz Soto; C Encalada; B Garro; I A G Sariego; M Guibert-Toledano; V J K Rodriguez; M E L Lopez; A P Ortega; A S Russell; P Santos-Moreno; I S Terán; A Vargas; G Vásquez; R M Xavier; D X Xibillé Firedman; E Mysler; J Kay
Journal:  Clin Rheumatol       Date:  2019-03-27       Impact factor: 2.980

Review 3.  Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view.

Authors:  Carlos Pineda; Carlo V Caballero-Uribe; Marcia Gonclaves de Oliveira; Pedro Saul Lipszyc; Jose Julian Lopez; Marcelo Mario Mataos Moreira; Valderilio Feijo Azevedo
Journal:  Clin Rheumatol       Date:  2015-02-12       Impact factor: 2.980

Review 4.  Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.

Authors:  Morton Scheinberg; Gilberto Castañeda-Hernández
Journal:  Arthritis Res Ther       Date:  2014-12-06       Impact factor: 5.156

Review 5.  Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.

Authors:  Eduardo Mysler; Carlos Pineda; Takahiko Horiuchi; Ena Singh; Ehab Mahgoub; Javier Coindreau; Ira Jacobs
Journal:  Rheumatol Int       Date:  2016-02-27       Impact factor: 2.631

Review 6.  Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Authors:  Morton Scheinberg; Carlos Pineda; Gilberto Castañeda-Hernández; Juan José Zarbá; Aderson Damião; Luiz H Arantes; Ira Jacobs
Journal:  MAbs       Date:  2018-08-29       Impact factor: 5.857

Review 7.  Biosimilars: potential implications for clinicians.

Authors:  Misty G Eleryan; Sophia Akhiyat; Monica Rengifo-Pardo; Alison Ehrlich
Journal:  Clin Cosmet Investig Dermatol       Date:  2016-06-17

Review 8.  Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?

Authors:  Valderilio Feijó Azevedo; Alejandra Babini; Carlo V Caballero-Uribe; Gilberto Castañeda-Hernández; Cecilia Borlenghi; Heather E Jones
Journal:  J Clin Rheumatol       Date:  2019-03       Impact factor: 3.517
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.